Terns Pharmaceuticals, Inc. (TERN) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $52.97: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: Below-average business quality; Rich valuation.
Terns Pharmaceuticals is a clinical-stage oncology company developing TERN-701, an oral allosteric BCR-ABL1 inhibitor for CML in Phase 1/2 (CARDINAL trial). The company entered a merger agreement with Merck Sharp & Dohme LLC at $53/share in March 2026; the merger closed May 5,... Read more
Sell if holding. Engine safety override at $52.97: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.6/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Terns Pharmaceuticals, Inc.
About Terns Pharmaceuticals, Inc.
TERN-701, an oral allosteric BCR-ABL1 inhibitor targeting chronic myeloid leukemia (CML), is Terns Pharmaceuticals' sole clinical program; at the recommended Phase 2 dose of ≥320mg once daily, the Phase 1/2 CARDINAL trial showed 75% major molecular response (MMR) achievement by 24 weeks as of a September 2025 data cut in a predominantly 3L+ patient population. Terns held $1.019 billion in cash, cash equivalents and marketable securities at December 31, 2025, against an accumulated deficit of $517.7 million and a net loss of $96.2 million in 2025.
Terns generates no product revenue and has funded operations entirely through equity raises since its December 2016 inception. TERN-701 targets CML, an orphan indication with approximately 17,000 new frontline patients per year across G7 nations and roughly 13,000 annual treatment switchers. The market is dominated by BCR-ABL1 kinase inhibitors: imatinib, four second-generation active-site TKIs (dasatinib, nilotinib, bosutinib, ponatinib), and asciminib—the first approved allosteric TKI from Novartis—which captured 23% of new-to-brand frontline share as of September 2025 and carries Novartis expectations of over $4 billion in peak annual sales. Terns plans a pivotal Phase 3 second-line-plus trial of TERN-701 against physician's choice of dasatinib, nilotinib, or bosutinib, with initiation targeted for late 2026 or early 2027, followed within 6 to 12 months by a separate frontline Phase 3 trial. The company's legacy metabolic programs—TERN-501 for MASH and TERN-801 for obesity—are being out-licensed to strategic partners.
Show full overview
The entire strategic value of Terns rests on a single binary outcome: whether TERN-701 achieves the MMR primary endpoint in the planned 2L+ Phase 3 trial, the design of which requires an End-of-Phase 2 regulatory interaction planned for mid-2026. An FDA decision not to accept the Phase 3 design, or a missed MMR endpoint, would eliminate the company's sole path to revenue. On May 5, 2026, Terns disclosed via Form 8-K completion of its acquisition by Merck Sharp & Dohme LLC at $53.00 per share, effectively resolving the standalone clinical risk trajectory.
See also: Healthcare · Biotechnology
From Terns Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-06-15Recent Developments — Terns Pharmaceuticals, Inc.
Latest news
- NEWS 'Merck Starts Seven-Part High-Grade Bond Sale to Fund Terns Deal' - Bloomberg — benzinga May 18, 2026 negative
- NEWS Oppenheimer Downgrades Terns Pharmaceuticals to Perform, Removes Price Target $58 — benzinga Apr 27, 2026 negative
- NEWS Terns Pharmaceuticals Wins FDA Breakthrough Therapy Designation For TERN-701 In Resistant CML — benzinga Apr 27, 2026 positive
- NEWS Merck's Waiting Period Expires Under Hart-Scott-Rodino Antitrust Improvements Act To Acquire Terns Pharmaceuticals — benzinga Apr 24, 2026 positive
- NEWS Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges — benzinga Apr 22, 2026 neutral
Generated 2026-06-17T08:56:48Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineTERN-70110-K Item 1A: 'Our business currently depends heavily on the successful development, marketing approval and commercialization of TERN-701'
Material Events(8-K, last 90d)
- 2026-05-05Item 5.01HIGHMerger with Merck Sharp & Dohme LLC completed May 5, 2026. Merger Sub merged with and into Terns; Terns surviving as a wholly-owned subsidiary of Merck. Shares delisted from Nasdaq.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $52.97: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $52.81. Score 4.6/10, moderate confidence.
Take-profit target: $51.92 (-1.9% upside). Prior stop was $52.81. Stop-loss: $52.81.
Concentration risk — Pipeline: TERN-701; Target reached (-14.9% upside); Quality below floor (1.6 < 4.0).
Terns Pharmaceuticals, Inc. trades at a P/E of N/A (forward -34.0). TrendMatrix value score: 3.0/10. Verdict: Sell.
17 analysts cover TERN with a consensus score of 3.5/5. Average price target: $53.
What does Terns Pharmaceuticals, Inc. do?Terns Pharmaceuticals is a clinical-stage oncology company developing TERN-701, an oral allosteric BCR-ABL1 inhibitor...
Terns Pharmaceuticals is a clinical-stage oncology company developing TERN-701, an oral allosteric BCR-ABL1 inhibitor for CML in Phase 1/2 (CARDINAL trial). The company entered a merger agreement with Merck Sharp & Dohme LLC at $53/share in March 2026; the merger closed May 5, 2026.